The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy


Autoria(s): Tamouza, Houda; Chemouny, Jonathan M.; Kafkova, Leona Raskova; Berthelot, Laureline; Flamant, Martin; Demion, Marie; Mesnard, Laurent; Paubelle, Etienne; Walker, Francine; Julian, Bruce A.; Tissandie, Emilie; Tiwari, Meetu K.; Câmara, Niels Olsen Saraiva; Vrtovsnik, Francois; Benhamou, Marc; Novak, Jan; Monteiro, Renato C.; Moura, Ivan C.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, has significant morbidity and mortality as 20-40% of patients progress to end-stage renal disease within 20 years of onset. In order to gain insight into the molecular mechanisms involved in the progression of IgAN, we systematically evaluated renal biopsies from such patients. This showed that the MAPK/ERK signaling pathway was activated in the mesangium of patients presenting with over 1 g/day proteinuria and elevated blood pressure, but absent in biopsy specimens of patients with IgAN and modest proteinuria (<1 g/day). ERK activation was not associated with elevated galactose-deficient IgA1 or IgG specific for galactose-deficient IgA1 in the serum. In human mesangial cells in vitro, ERK activation through mesangial IgA1 receptor (CD71) controlled pro-inflammatory cytokine secretion and was induced by large-molecular-mass IgA1-containing circulating immune complexes purified from patient sera. Moreover, IgA1-dependent ERK activation required renin-angiotensin system as its blockade was efficient in reducing proteinuria in those patients exhibiting substantial mesangial activation of ERK. Thus, ERK activation alters mesangial cell-podocyte crosstalk, leading to renal dysfunction in IgAN. Assessment of MAPK/ERK activation in diagnostic renal biopsies may predict the therapeutic efficacy of renin-angiotensin system blockers in IgAN. Kidney International (2012) 82, 1284-1296; doi:10.1038/ki.2012.192; published online 5 September 2012

Agence Nationale pour la Recherche (ANR JCJC)

Agence Nationale pour la Recherche (ANR JCJC)

Fondation pour la Recherche Medicale (FRM)

Fondation pour la Recherche Medicale (FRM) [ING20080914226]

ARC [SFI20111204013]

ARC

AAP du Programme National de Recherche en Nephrologie Urologie (PNR)

AAP du Programme National de Recherche en Nephrologie Urologie (PNR)

FAPESP-INSERM

FAPESPINSERM

CNPqINSERM

CNPq-INSERM

USP/COFECUB

USP/COFECUB

Societede Nephrologie

Societede Nephrologie

NIH

NIH [DK061525, DK078244, DK082753, DK083663, DK075868, GM098539]

Ministry of Education, Youth and Sport, Czech Republic

Ministry of Education, Youth and Sport, Czech Republic [MSM 6198959205, MSM 6198959216]

Identificador

KIDNEY INTERNATIONAL, NEW YORK, v. 82, n. 12, supl. 1, Part 3, pp. 1284-1296, DEC, 2012

0085-2538

http://www.producao.usp.br/handle/BDPI/37257

10.1038/ki.2012.192

http://dx.doi.org/10.1038/ki.2012.192

Idioma(s)

eng

Publicador

NATURE PUBLISHING GROUP

NEW YORK

Relação

KIDNEY INTERNATIONAL

Direitos

restrictedAccess

Copyright NATURE PUBLISHING GROUP

Palavras-Chave #IGA #IGA DEPOSITION #IGA NEPHROPATHY #FACTOR-KAPPA-B #MONOCYTE CHEMOATTRACTANT PROTEIN-1 #RESONANCE MASS-SPECTROMETRY #GALACTOSE-DEFICIENT IGA1 #TRANSFERRIN RECEPTOR #POLYMERIC IGA1 #KIDNEY-DISEASE #HINGE REGION #ABERRANT GLYCOSYLATION #PREDICTING PROGRESSION #UROLOGY & NEPHROLOGY
Tipo

article

original article

publishedVersion